146 related articles for article (PubMed ID: 10080617)
1. Health-related quality of life 1 year after allogeneic or autologous stem-cell transplantation: a prospective study.
Hjermstad MJ; Evensen SA; Kvaløy SO; Fayers PM; Kaasa S
J Clin Oncol; 1999 Feb; 17(2):706-18. PubMed ID: 10080617
[TBL] [Abstract][Full Text] [Related]
2. The course of anxiety and depression during the first year after allogeneic or autologous stem cell transplantation.
Hjermstad MJ; Loge JH; Evensen SA; Kvaløy SO; Fayers PM; Kaasa S
Bone Marrow Transplant; 1999 Dec; 24(11):1219-28. PubMed ID: 10642812
[TBL] [Abstract][Full Text] [Related]
3. The CARES-SF used for prospective assessment of health-related quality of life after stem cell transplantation.
Hjermstad MJ; Evensen SA; Kvaløy SO; Loge JH; Fayers PM; Kaasa S
Psychooncology; 2003 Dec; 12(8):803-13. PubMed ID: 14681953
[TBL] [Abstract][Full Text] [Related]
4. A prospective study of health-related quality of life, fatigue, anxiety and depression 3-5 years after stem cell transplantation.
Hjermstad MJ; Knobel H; Brinch L; Fayers PM; Loge JH; Holte H; Kaasa S
Bone Marrow Transplant; 2004 Aug; 34(3):257-66. PubMed ID: 15170167
[TBL] [Abstract][Full Text] [Related]
5. Do patients who are treated with stem cell transplantation have a health-related quality of life comparable to the general population after 1 year?
Hjermstad M; Holte H; Evensen S; Fayers P; Kaasa S
Bone Marrow Transplant; 1999 Oct; 24(8):911-8. PubMed ID: 10516705
[TBL] [Abstract][Full Text] [Related]
6. Health-related quality of life in patients undergoing allogeneic stem cell transplantation after reduced intensity conditioning versus myeloablative conditioning.
Andersson I; Ahlberg K; Stockelberg D; Brune M; Persson LO
Cancer Nurs; 2009; 32(4):325-34. PubMed ID: 19444087
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of the effectiveness of chemotherapy and autologous hematopoietic stem cell transplantation as postremission treatment for adult acute lymphoblastic leukemia patients].
Jin FY; Zou DH; Wang GR; Xu Y; Feng SZ; Zhao YZ; Han MZ; Yan WW; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2005 Nov; 26(11):645-8. PubMed ID: 16620547
[TBL] [Abstract][Full Text] [Related]
8. Patients' perception of health-related quality of life during the first year after autologous and allogeneic stem cell transplantation.
Andersson I; Ahlberg K; Stockelberg D; Persson LO
Eur J Cancer Care (Engl); 2011 May; 20(3):368-79. PubMed ID: 20345452
[TBL] [Abstract][Full Text] [Related]
9. Defects in lymphocyte subsets and serological memory persist a median of 10 years after high-dose therapy and autologous progenitor cell rescue for malignant lymphoma.
Dean HF; Cazaly A; Hurlock C; Borras J; Williams AP; Johnson PW; Davies AJ
Bone Marrow Transplant; 2012 Dec; 47(12):1545-51. PubMed ID: 22580768
[TBL] [Abstract][Full Text] [Related]
10. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
11. Mucositis after reduced intensity conditioning and allogeneic stem cell transplantation.
Busemann C; Wilfert H; Neumann T; Kiefer T; Dölken G; Krüger WH
Onkologie; 2011; 34(10):518-24. PubMed ID: 21985850
[TBL] [Abstract][Full Text] [Related]
12. High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group.
Sweetenham JW; Santini G; Qian W; Guelfi M; Schmitz N; Simnett S; Nagler A; Holte H; Kvaloy S; Bruzzi P; Goldstone AH
J Clin Oncol; 2001 Jun; 19(11):2927-36. PubMed ID: 11387366
[TBL] [Abstract][Full Text] [Related]
13. Pattern of employment and associated factors in long-term lymphoma survivors 10 years after high-dose chemotherapy with autologous stem cell transplantation.
Kiserud CE; Fagerli UM; Smeland KB; Fluge Ø; Bersvendsen H; Kvaløy S; Holte H; Dahl AA
Acta Oncol; 2016 May; 55(5):547-53. PubMed ID: 27123741
[TBL] [Abstract][Full Text] [Related]
14. Temporal trajectory of quality of life and its predictors in recipients of hematopoietic stem cell transplantation.
Kim R; Son KL; Lee KM; Choi Y; Hong J; Shin DY; Koh Y; Hahm BJ; Kim I
Ann Hematol; 2018 Aug; 97(8):1407-1415. PubMed ID: 29616316
[TBL] [Abstract][Full Text] [Related]
15. Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support.
Gulbrandsen N; Wisløff F; Brinch L; Carlson K; Dahl IM; Gimsing P; Hippe E; Hjorth M; Knudsen LM; Lamvik J; Lenhoff S; Løfvenberg E; Nesthus I; Nielsen JL; Turesson I; Westin J;
Med Oncol; 2001; 18(1):65-77. PubMed ID: 11778972
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
[TBL] [Abstract][Full Text] [Related]
17. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
Illerhaus G; Marks R; Ihorst G; Guttenberger R; Ostertag C; Derigs G; Frickhofen N; Feuerhake F; Volk B; Finke J
J Clin Oncol; 2006 Aug; 24(24):3865-70. PubMed ID: 16864853
[TBL] [Abstract][Full Text] [Related]
18. Graft versus host disease in autologous stem cell transplantation.
Marin GH; Porto A; Prates V; Napal J; Etchegogen O; Rubens L; Bordone J; Castelletto R; Buschiazzo H; Morales V; Milone J
J Exp Clin Cancer Res; 1999 Jun; 18(2):201-8. PubMed ID: 10464707
[TBL] [Abstract][Full Text] [Related]
19. Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group.
Lenz G; Dreyling M; Schiegnitz E; Haferlach T; Hasford J; Unterhalt M; Hiddemann W
J Clin Oncol; 2004 Dec; 22(24):4926-33. PubMed ID: 15611507
[TBL] [Abstract][Full Text] [Related]
20. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
Becherer A; Mitterbauer M; Jaeger U; Kalhs P; Greinix HT; Karanikas G; Pötzi C; Raderer M; Dudczak R; Kletter K
Leukemia; 2002 Feb; 16(2):260-7. PubMed ID: 11840293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
